Innate Pharma S.A. (EPA:IPH)
France · Delayed Price · Currency is EUR 1.908
+0.128 (7.19%)
Aug 21, 2026, 5:35 PM CET
[Name] Stock Forecast
Stock Price Forecast
According to 2 analysts polled by S&P Global, [Name] stock has a consensus rating of "Strong Buy" and an average price target of €5.90. The average 1-year stock price forecast is 209.22% higher than the current stock price, while the lowest is €5.60 (+193.50%) and the highest is €6.20 (+224.95%).
Price Target: €5.90 (+209.22%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for [Name] stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Jan '26 | Feb '26 | Mar '26 | Jun '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 1 | 2 | 2 | 2 |
Financial Forecast
Revenue This Year
40.33M
from 9.01M
Increased by 347.85%
Revenue Next Year
96.63M
from 40.33M
Increased by 139.60%
EPS This Year
0.95
EPS Next Year
2.15
from 0.95
Increased by 126.32%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.